Info

Concluding Remarks

In this chapter we have described the binding modes of some CK2 inhibitors that target the ATP-binding site. These inhibitors belong to different chemical families and have inhibitory constants in the low micromolar range. Two of them, namely TBB and IQA, display a significant selectivity among panels of tens of different kinases, and can be considered an encouraging starting point for the development of compounds of potential pharmacological interest.

For all the inhibitors here described, the main energetic contribution to the binding is attributed to hydrophobic interaction with the apolar surface region of the CK2 binding cleft. In this respect, the shape and the reduced dimension of the CK2 active site in comparison with other kinases are essential in explaining the selectivity of these inhibitors as well as the anomalous low potency of staurosporine. In particular, isoleucine/valine-66 and isoleucine-174, residues unique to CK2, play an important role as demonstrated by mutagenesis studies. The aromatic nature of the inhibitors can be considered a key characteristic of these compounds, providing the main energetic contribution to the binding.

In general, the ATP-binding sites of kinases present both polar and hydrophobic portions. While the characteristics of the polar moiety are quite conserved among the family, as, for instance, some key residues in the hinge regions, in the phosphate anchor region, or other residues like lysine-68, glu-tamate-81, and aspartate-175 (CK2 numbering), the hydrophobic ones have a higher degree of variability in the amino acid composition. Consequently, the selectivity is ensured by targeting the hydrophobic portion of the bind ing site while the presence of polar interactions (hydrogen bonds, salt bridges) enhances the potency of the inhibitor. The inhibitors here described can be considered more selective than potent, and this is in agreement with the above considerations in that they bind to the enzyme mainly through hydro-phobic interactions. As noticed for the four anthraquinones, the presence of polar interactions is essential to increase the binding potency; in this respect, the interactions with the hinge region seem more effective (see the case of DAA in comparison with emodin). To produce inhibitors in the nanomolar range, as would be desirable, our aim is now concentrated in the increase of the number and strength of the polar interactions between the inhibitors and the enzyme, without depleting the hydrophobic interactions. Other important points are the increase of the solubility of these compounds in water and the analysis of their potential pharmacological properties.

The estimate of the selectivity of a kinase inhibitor is always a difficult task; in fact, while the number of kinases has been estimated around 500 from the human genome, the enzymes really available for inhibition assays are only a fraction of that (around some tens). The development of enzyme mutants resistant to the inhibitory activity of a specific compound but with a catalytic activity similar to the wild-type protein [i.e., mutants Ile66Ala and Ile174Ala for CK2 (Sarno et al. 2002)] can be very useful in the analysis of its selectivity. In fact, the recovery of the original kinase activity by means of such mutants in the presence of the specific inhibitor in in vivo assays can be considered a validation of the involvement of just that kinase in the process under study.

References

Ahmed K, Gerber DA, Cochet C (2002) Joining the cell survival squad: an emerging role for protein kinase CK2. Trends Cell Biol 12:226-230 Ali AM, Ismail NH, Mackeen MM, Yazan LS, Mohamed SM, Ho ASH, Lajis NH (2000) Antiviral, cytotoxic and antimicrobial activities of anthraquinones isolated from the roots of Morinda elliptica. Pharm Biol 38:298-301 Battistutta R, Sarno S, De Moliner E, Papinutto E, Zanotti G, Pinna LA (2000) The replacement of ATP by the competitive inhibitor emodin induces conformational modifications in the catalytic site of protein kinase CK2. J Biol Chem 275:29618-29622 Battistutta R, De Moliner E, Sarno S, Zanotti G, Pinna LA (2001) Structural features underlying selective inhibition of protein kinase CK2 by ATP site-directed tetrabromo-2-benzotriazole. Protein Sci 10:2200-2206 Buchou T, Vernet M, Blond O, Jensen HH, Pointu H, Olsen BB, Cochet C, Issinger OG, Boldyreff B (2003) Disruption of the regulatory beta subunit of protein kinase CK2 in mice leads to a cell-autonomous defect and early embryonic lethality. Mol Cell Biol 23:908-915

Burnett G, Kennedy EP (1954) The enzymatic phosphorylation of proteins. J Biol Chem 211:969-980

Chan TC, Chang CJ, Koonchanok NM, Geahlen RL (1993) Selective inhibition of the growth of ras-transformed human bronchial epithelial cells by emodin, a protein-ty-rosine kinase inhibitor. Biochem Biophys Res Commun 193:1152-1158 Chantalat L, Leroy D, Filhol O, Nueda A, Benitez MJ, Chambaz EM, Cochet C, Dideberg O

(1999) Crystal structure of the human protein kinase CK2 regulatory subunit reveals its zinc finger-mediated dimerization. EMBO J 18:2930-2940

Chardot T, Shen H, Meunier JC (1995) Dual specificity of casein kinase II from the yeast

Yarrowia lipolytica. C R Acad Sci III 318:937-942 Cohen P (2002) Protein kinases: the major drug targets of the twenty-first century? Nat

Rev Drug Discov 1:309-315 Davis ST, Benson BG, Bramson HN, Chapman DE, Dickerson SH, Dold KM, Eberwein DJ, Edelstein M, Frye SV, Gampe Jr RT, Griffin RJ, Harris PA, Hassell AM, Holmes WD, Hunter RN, Knick VB, Lackey K, Lovejoy B, Luzzio MJ, Murray D, Parker P, Rocque WJ, Shewchuk L, Veal JM, Walker DH, Kuyper LF (2001) Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors. Science 291:134-137 De Moliner E, Moro S, Sarno S, Zagotto G, Zanotti G, Pinna LA, Battistutta R (2003) Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight. J Biol Chem 278:1831-1836 Donella-Deana A, Cesaro L, Sarno S, Brunati AM, Ruzzene M, Pinna LA (2001) Autocata-lytic tyrosine-phosphorylation of protein kinase CK2 alpha and alpha' subunits: implication of Tyr182. Biochem J 357:563-567 Engh RA, Bossemeyer D (2002) Structural aspects of protein kinase control-role of con-

formational flexibility. Pharmacol Ther 93:99-111 Ermakova I, Boldyreff B, Issinger OG, Niefind K (2003) Crystal structure of a C-terminal deletion mutant of human protein kinase CK2 catalytic subunit. J Mol Biol 330:925934

Faust M, Montenarh M (2000) Subcellular localization of protein kinase CK2. A key to its function? Cell Tissue Res 301:329-340 Fraser AG, Kamath RS, Zipperlen P, Martinez-Campos M, Sohrmann M, Ahringer J

(2000) Functional genomic analysis of C. elegans chromosome I by systematic RNA interference. Nature 408:325-330

Fredenhagen A, Mett H, Meyer T, Buchdunger E, Regenass U, Roggo BE, Petersen F (1995) Protein tyrosine kinase and protein kinase C inhibition by fungal an-thraquinones related to emodin. J Antibiot Tokyo 48:1355-1358 Garcia-Echeverria C, Traxler P, Evans DB (2000) ATP site-directed competitive and irreversible inhibitors of protein kinases. Med Res Rev 20:28-57 Goel S, Mani S, Perez Soler R (2002) Tyrosine kinase inhibitors: a clinical perspective.

Curr Oncol Rep 4:9-19 Graham KC, Litchfield DW (2000) The regulatory beta subunit of protein kinase CK2 mediates formation of tetrameric CK2 complexes. J Biol Chem 275:5003-5010 Gray NS, Wodicka L, Thunnissen AM, Norman TC, Kwon S, Espinoza FH, Morgan DO, Barnes G, LeClerc S, Meijer L, Kim SH, Lockhart DJ, Schultz PG (1998) Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science 281:533-538

Guerra B, Issinger OG (1999) Protein kinase CK2 and its role in cellular proliferation, development and pathology. Electrophoresis 20:391-408 Hanks SK, Hunter T (1995) Protein kinases 6. The eukaryotic protein kinase superfamily:

kinase (catalytic) domain structure and classification. FASEB J 9:576-596 Hardcastle IR, Golding BT, Griffin RJ (2002) Designing inhibitors of cyclin-dependent ki-nases. Annu Rev Pharmacol Toxicol 42:325-348

Huse M, Kuriyan J (2002) The conformational plasticity of protein kinases. Cell 109:275282

Jayasuriya H, Koonchanok NM, Geahlen RL, McLaughlin JL, Chang CJ (1992) Emodin, a protein tyrosine kinase inhibitor from Polygonum cuspidatum. J Nat Prod 55:696698

Jeffrey PD, Russo AA, Polyak K, Gibbs E, Hurwitz J, Massague J, Pavletich NP (1995) Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex. Nature 376:313-320

Johnson LN, Noble ME, Owen DJ (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85:149-158 Litchfield DW (2003) Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. Biochem J 369:1-15 Manning G, Plowman GD, Hunter T, Sudarsanam S (2002a) Evolution of protein kinase signaling from yeast to man. Trends Biochem Sci 27:514-520 Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002b) The protein kinase complement of the human genome. Science 298:1912-1934 Marin O, Meggio F, Sarno S, Cesaro L, Pagano MA, Pinna LA (1999) Tyrosine versus serine/threonine phosphorylation by protein kinase casein kinase-2. A study with pep-tide substrates derived from immunophilin Fpr3. J Biol Chem 274:29260-29265 Meggio F, Marin O, Pinna LA (1994) Substrate specificity of protein kinase CK2. Cell Mol Biol Res 40:401-409

Meggio F, Donella Deana A, Ruzzene M, Brunati AM, Cesaro L, Guerra B, Meyer T, Mett H, Fabbro D, Furet P, Dobrowolska G, Pinna LA (1995) Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2. Eur J Biochem 234:317-322 Meggio F, Pinna LA (2003) One-thousand-and-one substrates of protein kinase CK2? FASEB J 17:349-368

Niefind K, Guerra B, Pinna LA, Issinger OG, Schomburg D (1998) Crystal structure of the catalytic subunit of protein kinase CK2 from Zea mays at 2.1 Ä resolution. EMBO J 17:2451-2462

Niefind K, Putter M, Guerra B, Issinger OG, Schomburg D (1999) GTP plus water mimic

ATP in the active site of protein kinase CK2. Nat Struct Biol 6:1100-1103 Niefind K, Guerra B, Ermakowa I, Issinger OG (2001) Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO J 20:53205331

Padmanabha R, Chen Wu JL, Hanna DE, Glover CV (1990) Isolation, sequencing, and disruption of the yeast CKA2 gene: casein kinase II is essential for viability in Saccha-romyces cerevisiae. Mol Cell Biol 10:4089-4099 Parang K, Cole PA (2002) Designing bisubstrate analog inhibitors for protein kinases.

Pharmacol Ther 93:145-157 Parang K, Till JH, Ablooglu AJ, Kohanski RA, Hubbard SR, Cole PA (2001) Mechanism-

based design of a protein kinase inhibitor. Nat Struct Biol 8:37-41 Pechkova E, Zanotti G, Nicolini C (2003) Three-dimensional atomic structure of a catalytic subunit mutant of human protein kinase CK2. Acta Cryst D 59:2133-2139 Pinna LA (2002) Protein kinase CK2: a challenge to canons. J Cell Sci 115:3873-3878 Pinna LA, Meggio F (1997) Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation. Prog Cell Cycle Res 3:77-97 Sarno S, Vaglio P, Meggio F, Issinger OG, Pinna LA (1996) Protein kinase CK2 mutants defective in substrate recognition. Purification and kinetic analysis. J Biol Chem 271:10595-10601

Sarno S, Moro S, Meggio F, Zagotto G, Dal Ben D, Ghisellini P, Battistutta R, Zanotti G, Pinna LA (2002) Toward the rational design of protein kinase casein kinase-2 inhibitors. Pharmacol Ther 93:159-168 Sarno S, De Moliner E, Ruzzene M, Pagano MA, Battistutta R, Bain J, Fabbro D, Schoepfer J, Elliott M, Furet P, Meggio F, Zanotti G, Pinna LA (2003) Biochemical and 3D-struc-tural data on the specific inhibition of protein kinase CK2 by (5-oxo-5,6-dihydro-in-dolo(1,2-a)quinazolin-7-yl)acetic acid (IQA). Biochem J 374:639-646 Sarno S, Reddy H, Meggio F, Ruzzene M, Davies SP, Donella Deana A, Shugar D, Pinna LA (2001) Selectivity of 4,5,6,7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'). FEBS Lett 496:44-48 Scapin G (2002) Structural biology in drug design: selective protein kinase inhibitors.

Drug Discov Today 7:601-611 Seldin DC, Leder P (1995) Casein kinase II alpha transgene-induced murine lymphoma:

relation to theileriosis in cattle [see comments]. Science 267:894-897 Shugar D (1999) Viral and host-cell protein kinases: enticing antiviral targets and relevance of nucleoside, and viral thymidine, kinases. Pharmacol Ther 82:315-335 Stahura FL, Xue L, Godden JW, Bajorath J (1999) Molecular scaffold-based design and comparison of combinatorial libraries focused on the ATP-binding site of protein ki-nases. J Mol Graph Model 17:1-9:51-52 Szyszka R, Grankowski N, Felczak K, Shugar D (1995) Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccha-romyces cerevisiae and other sources. Biochem Biophys Res Commun 208:418-424 Tawfic S, Yu S, Wang H, Faust R, Davis A, Ahmed K (2001) Protein kinase CK2 signal in neoplasia. Histol histopathol 16:573-582 Toledo LM, Lydon NB, Elbaum D (1999) The structure-based design of ATP-site directed protein kinase inhibitors. Curr Med Chem 6:775-805 Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J (2001) Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 21:499-512 Vangrevelinghe E, Zimmermann K, Schoepfer J, Portmann R, Fabbro D, Furet P (2003) Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J Med Chem 46:2656-2662 Yim H, Lee YH, Lee CH, Lee SK (1999) Emodin, an anthraquinone derivative isolated from the rhizomes of Rheum palmatum, selectively inhibits the activity of casein ki-nase II as a competitive inhibitor. Planta Med 65:9-13 Young TA, Delagoutte B, Endrizzi JA, Falick AM, Alber T (2003) Structure of Mycobacterium tuberculosis PknB supports a universal activation mechanism for Ser/Thr protein kinases. Nat Struct Biol 10:168-174 Zandomeni R, Zandomeni MC, Shugar D, Weinmann R (1986) Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. J Biol Chem 261:3414-3419 Zhang L, Lau YK, Xi L, Hong RL, Kim DS, Chen CF, Hortobagyi GN, Chang C, Hung MC (1998) Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. Oncogene 16:2855-2863

HEP (2005) 167:157-188 © Springer-Verlag 2005

Was this article helpful?

0 0
100 Hair Growth Tips

100 Hair Growth Tips

100 Hair Growth Tips EVERY Balding Person Should Know. This Report

Get My Free Ebook


Post a comment